Clinical Trials
Scientists at PNDRI engage in clinical as well as basic research in pursuit of preventing and curing diabetes and its complications. Below are the trials for which Institute investigators are currently recruiting. For a national listing of clinical trials, please visit the federal registry at www.clinicaltrials.gov.
Type 1 Diabetes Trials
Protégé Encore Clinical Research Study
Newly diagnosed type 1 diabetics and individuals who recently experienced their first symptoms of the disease are invited to participate in a clinical research study to evaluate an investigational drug that may help slow or even stop the progression of type 1 diabetes. Protégé Encore is led by PNDRI Scientific Director Bill Hagopian, M.D., Ph.D.
To participate in this study, volunteers must:
- Have had their first doctor visit for symptoms of type 1 diabetes and received that diagnosis less than 12 weeks before starting the study treatment
- Be 14 to 35 years of age
- Weigh at least 79 lbs (36 kg)
- Not have had certain vaccinations within 4-8 weeks of study entry
Volunteers will receive, at no cost, study-related:
- Diabetes monitoring
- Direct access to doctors or nurses to answer questions and concerns
- Physical exams and blood work
- Investigational study drug or placebo
- Glucose monitor and supplies
For more information about Protégé Encore, please contact Rachel Hervey at (206) 568-1485 or rhervey@pndri.org.
Type 2 Diabetes Trials
Antioxidant Treatment of Type 2 Diabetes
This study is led by Principal Scientist R. Paul Robertson, M.D., and examines whether an antioxidant taken orally will improve glucose tolerance and insulin secretion in type 2 diabetics.
To participate in this study, volunteers must:
- Be 18 to 70 years of age
- Have known diagnosis of type 2 diabetes
- Not have known intolerance to n-acetylcysteine
For more information on this clinical trial and how you can participate, please visit the study's website.